Compare Global X Defense Tech ETF (SHLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Global X Defense Tech ETF trades at $70.68, while State Street SPDR S&P Biotech ETF trades at $159.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| SHLD | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $78.02 | $164.28 |
52-Week Low | $58.20 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $70.15, up 0.43% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from increased institutional interest with multiple firms raising stakes in Q2 2026, while geopolitical tensions and rising global defense spending underpin sector tailwinds. However, key oscillators show neutral to overbought conditions with RSI levels above 78, suggesting potential near-term consolidation.
The defense technology sector outlook remains favorable amid elevated military budgets worldwide, though SHLD faces competition from similar ETFs and sensitivity to geopolitical developments. Current technical strength supports bullish momentum, but investors should monitor RSI levels for overextension risks amid evolving defense policy shifts.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
